About Michael Cima
Michael Cima is an independent director at GelMEDIX.
Michael Cima reports to the SEC as a director of 1 public company: T2 Biosystems (TTOO).
Michael Cima first appears on SEC filings in 2014.
Experience
This experience comes from Michael Cima's profile and from SEC filings. For roles taken from filings, the years are when the filings name Michael Cima in the role, so the role may have started earlier or lasted longer.
GelMEDIX, Inc. Current
Independent Director
2021 – Present · Cambridge, MA
Develops regenerative therapies for people with vision loss.
RH
Ravada Health Current
Director and Founder
2020 – Present
TI
T2 Biosystems, Inc. Current
Director
2011 – Present · Public company (TTOO)
MT
Massachusetts Institute of Technology Current
Koch Professor of Engineering
1986 – Present
MI
MicroChips
Director
2012 – 2023
TB
Taris Biomedical
Director
2008 – 2023
MI
MIT
Associate Dean of Engineering, Co-director of MIT Innovation Initiative
2018 – 2021
TV
ThirdRock Ventures
portfolio company
2011 – 2015
ST
SpringLeaf Therapeutics
Director
2008 – 2013
JN
JNJ
consultant
2000 – 2005
TP
Transform Pharmaceuticals
Consultant
1999 – 2005
Key Colleagues at Startups
The people Michael Cima works with at each company, as listed on that company's latest Form D.
GelMEDIX, Inc. · Form D/A, Apr 30, 2026
NA
Nasim Annabi
Co-Founder and director
RD
Reza Dana
Co-Founder and director
PM
Parinaz Motamedy
Safar Partners - Lead Investor and director
Max Cotler
Chief Executive Officer and director